Table 1. Patient Characteristics at Baseline.
| Characteristic | No. | Tocilizumab, No./No. (%) | No. | Usual care, No./No. (%) |
|---|---|---|---|---|
| No. | 63 | 67 | ||
| Age, median (IQR), y | 64.0 (57.1-74.3) | 63.3 (57.1-72.3) | ||
| Male | 44/63 (70) | 44/67 (66) | ||
| Female | 19/63 (30) | 23/67 (34) | ||
| Weight, median (IQR), kg | 80.0 (70.0-90.0) | 55 | 78.0 (70.0-90.0) | |
| BMI,a median (IQR) | 46 | 27.9 (23.3-30.8) | 46 | 27.4 (24.5-31.3) |
| WHO-CPS score (0-10) = 5 | 63/63 (100) | 67/67 (100) | ||
| rRT-PCR–confirmed SARS-CoV-2 infection | 56/63 (89) | 61/67 (90) | ||
| Temperature, median (IQR), °C | 37.3 (36.8-38.2) | 37.9 (37.0-38.6) | ||
| Respiratory rate, median (IQR), bpm | 56 | 24.0 (22.0-30.0) | 57 | 26.0 (24.0-30.0) |
| Flow, median (IQR), L/min | 5.0 (3.0-8.0) | 5.0 (3.0-6.0) | ||
| SpO2, median (IQR), % | 95.0 (93.0-96.0) | 95.0 (93.0-97.0) | ||
| Time from symptoms onset to randomization, median (IQR), d | 62 | 10 (7-13) | 66 | 10 (8-13) |
| Time from hospital admission to randomization, median (IQR), d | 63 | 1 (1-4) | 67 | 1 (1-2) |
| Coexisting conditions | ||||
| Chronic cardiac disease | 20/61 (33) | 20/67 (30.0) | ||
| Diabetes | 20/61 (33) | 23/67 (34) | ||
| Chronic kidney disease (stage 1 to 3) or dialysis | 5/61 (8) | 13/67 (19) | ||
| Asthma | 5/61 (8) | 3/67 (5) | ||
| Chronic pulmonary disease (not asthma) | 3/61 (5) | 3/67 (5) | ||
| Active malignant neoplasm | 4/61 (7) | 5/67 (8) | ||
| Smoking | ||||
| No | 55/61 (90) | 62/67 (93) | ||
| Current | 1/61 (2) | 2/67 (3) | ||
| Former | 5/61 (8) | 3/67 (4) | ||
| Laboratory values, median (IQR) | ||||
| CRP, mg/L | 56 | 119.5 (74.5-219.5) | 63 | 127.0 (84.0-171.0) |
| D-Dimer, μg/L | 50 | 869 (524-1380) | 50 | 1250 (780-1812) |
| Neutrophil count, G/L | 60 | 4.9 (3.9-7.5) | 63 | 5.1 (3.4-6.6) |
| Lymphocyte count, G/L | 60 | 1.0 (0.7-1.4) | 60 | 1.1 (0.6-1.2) |
| Lymphocytes to neutrophils ratio | 48 | 0.2 (0.1-0.3) | 40 | 0.2 (0.1-0.3) |
| Hemoglobin, g/dL | 62 | 12.8 (11.9-13.8) | 65 | 12.3 (10.9-13.4) |
| Platelet count, g/L | 62 | 230 (187-324) | 65 | 226 (163-286) |
| ALT/SGPT, IU/L | 57 | 40.0 (30.0-67.0) | 62 | 35.0 (22.0-55.0) |
| AST/SGOT, IU/L | 58 | 50.0 (34.0-66.0) | 62 | 55.0 (36.0-74.0) |
| Albumin, g/L | 43 | 30.0 (27.0-36.0) | 42 | 32.2 (28.0-36.0) |
| Creatinine, μmol/L | 61 | 71.0 (56.0-87.0) | 64 | 75.0 (59.5-119.5) |
| Blood urea, mmol/L | 62 | 5.8 (4.4-7.7) | 65 | 5.1 (4.2-8.6) |
| Ferritin, mg/L | 43 | 1292 (424-2484) | 46 | 1070 (563-1790) |
| LDH, IU/L | 46 | 401 (313-582) | 51 | 434 (351-558) |
| CPK, IU/L | 42 | 136.0 (48.0-284.0) | 41 | 105.0 (67.0-236.0) |
Abbreviations: ALD, alanine aminotransferase; ALT/SGOT, alanine transaminase; AST, aspartate aminotransferase; BPM, breaths per min; CPK, creatine phosphokinase; CRP, C-reactive protein; IQR, interquartile range; LDH, lactate dehydrogenase, rRT-PCR, real-time reverse transcription polymerase chain reaction; SpO2, oxygen saturation; WHO-CPS World Health Organization 10-point Clinical Progression Scale.
a
Body mass index, calculated as weight in kilograms divided by height in meters squared